MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Smith from Leerink Partners maintained a Buy rating on the stock and has a $73.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Thomas Smith’s rating is based on MoonLake Immunotherapeutics’ promising clinical developments and strategic positioning. The company is on the verge of releasing highly anticipated Phase 3 data for its sonelokimab treatment in hidradenitis suppurativa, which could unlock significant commercial opportunities if results meet expectations. Additionally, the ongoing Phase 2 trial in palmoplantar pustulosis has shown encouraging interim results, suggesting potential differentiation from competitors in a market with ample development space.
Furthermore, the upcoming Phase 3 results for sonelokimab in psoriatic arthritis are expected to enhance its strategic value, given its compelling data across multiple indications. The company’s strong clinical execution in dermatology and rheumatology, coupled with the potential for best-in-class results, positions it well for future growth and strategic interest. Overall, these factors contribute to the Buy rating, reflecting confidence in MoonLake’s ability to capitalize on substantial market opportunities.
In another report released yesterday, Wedbush also maintained a Buy rating on the stock with a $80.00 price target.
MLTX’s price has also changed moderately for the past six months – from $53.770 to $44.020, which is a -18.13% drop .
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue